SCOPUS 정보 검색 플랫폼

Archives of Disease in Childhood

Volumn 91, Issue 3, 2006, Pages 209-210

Newborn screening for cystic fibrosis: Do we need a second IRT?

(1) Price, J F a

a KING S COLLEGE HOSPITAL (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRYPSINOGEN;

CLINICAL PROTOCOL; CYSTIC FIBROSIS; DNA DETERMINATION; GENE MUTATION; HUMAN; IMMUNOREACTIVITY; LUNG FUNCTION; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL; SHORT SURVEY;

BIOLOGICAL MARKERS; CYSTIC FIBROSIS; GENETIC SCREENING; GREAT BRITAIN; HUMANS; INFANT, NEWBORN; MUTATION; NEONATAL SCREENING; TRYPSINOGEN;

EID: 33644648971 PISSN: 00039888 EISSN: 14682044 Source Type: Journal
DOI: 10.1136/adc.2005.085084 Document Type: Short Survey

Times cited : (8)

References (7)

1
- 25144492375
- Newborn screening for cystic fibrosis is associated with reduced treatment intensity
- Sims EJ, McCormick J, Mehta G, et al. Newborn screening for cystic fibrosis is associated with reduced treatment intensity. J Pediatr 2005;147:306-11.
- (2005) J Pediatr , vol.147 , pp. 306-311
- Sims, E.J.¹ McCormick, J.² Mehta, G.³

2
- 3343023861
- Early intervention and prevention of lung disease in cystic fibrosis: A European consensus
- Consensus Study Group
- Doring G, Hoiby N. Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cystic Fibrosis 2004;3:67-91.
- (2004) J Cystic Fibrosis , vol.3 , pp. 67-91
- Doring, G.¹ Hoiby, N.²

3
- 33644661639
- Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis mutations is not an indication for further testing
- Massie J, Curnow L, Tzanakos N, et al. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis mutations is not an indication for further testing. Arch Dis Child 2006;91:222-5.
- (2006) Arch Dis Child , vol.91 , pp. 222-225
- Massie, J.¹ Curnow, L.² Tzanakos, N.³

4
- 33644641891
- Personal communication to the UK Newborn Screening Program Centre
- Doull I, Hall S, Bradley D. Newborn screening for cystic fibrosis. The Welsh Experience, 1996-2004. Personal communication to the UK Newborn Screening Program Centre, 2004.
- (2004) Newborn Screening for Cystic Fibrosis. The Welsh Experience, 1996-2004
- Doull, I.¹ Hall, S.² Bradley, D.³

5
- 0345479163
- Implications of carrier identification in newborn screening for cystic fibrosis
- Parsons EP, Clarke AJ, Bradley DM. Implications of carrier identification in newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 2003;88:F467-71.
- (2003) Arch Dis Child Fetal Neonatal Ed , vol.88
- Parsons, E.P.¹ Clarke, A.J.² Bradley, D.M.³

6
- 0036801803
- Demographics of the UK cystic fibrosis population: Implications for neonatal screening
- McCormick J, Green M, Mehta G, et al. Demographics of the UK cystic fibrosis population: implications for neonatal screening. Eur J Hum Genet 2002;10:583-90.
- (2002) Eur J Hum Genet , vol.10 , pp. 583-590
- McCormick, J.¹ Green, M.² Mehta, G.³

7
- 25144480567
- Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis
- Sarles J, Berthezene P, Le Louarn C Somma C, et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 2005;147:302-5.
- (2005) J Pediatr , vol.147 , pp. 302-305
- Sarles, J.¹ Berthezene, P.² Le Louarn, C.³ Somma, C.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.